MedTrace Logo

Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease

NCT04736966 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-08-06

No results posted yet for this study

Summary

A Phase I clinical trial to determine the safety and tolerability of an anti-IL23 antibody for the treatment of patients with alcoholic liver disease

Conditions

Interventions

DRUG

Guselkumab 30mg

30mg of Guselkumab administered by subcutaneous injection

DRUG

Guselkumab 70mg

70mg of Guselkumab administered by subcutaneous injection

DRUG

Guselkumab 100mg

100mg of Guselkumab administered by subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Rohit Loomba · University of California, San Diego

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2024-03-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04736966 on ClinicalTrials.gov